Dr. Reddy's Laboratories Limited American Depositary Shares
RDYDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| $0.11 | 2003-08-07 | 2003-08-11 | |
| $0.08 | 2026-07-24 | 2026-07-09 | |
| August 6, 2025 | $0.09 | 2025-07-25 | 2025-07-10 |
| August 12, 2024 | $0.48 | 2024-07-30 | 2024-07-15 |
| August 11, 2023 | $0.48 | 2023-07-28 | 2023-07-10 |
Dividends Summary
- Total Returned Value: Investors who held RDY shares during this period received a total of $5.39 per share in dividend income.
- Latest Payout: The most recent dividend of $0.11/share was paid 346 days ago, on August 6, 2025.
- Dividend Growth: Since 2004, the dividend payout has decreased by 0.3%, from $0.11 to $0.11.
Company News
The global generic drug market is projected to grow from USD 491.35 billion in 2024 to USD 926.54 billion by 2034, expanding at a CAGR of 6.55%. Growth is driven by increasing demand for cost-effective medicines, rising chronic diseases, and aging populations, particularly in North America and Asia-Pacific regions. However, the market faces chall...
Following the expiration of India's semaglutide patent, over 40 Indian pharmaceutical companies have launched generic versions of Novo Nordisk's Ozempic and Wegovy at dramatically reduced prices—approximately 70% cheaper than originals. Major players like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering monthly ...
The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include risi...
The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.
The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.
